Skyhawk Therapeutics Partners with Merck KGaA for Innovative Neurological Drug Development Skyhawk Therapeutics has teamed up with Merck KGaA, Darmstadt, Germany, to explore groundbreaking RNA-targeting therapies for neurological disorders. This collaboration holds a deal value over $2 billion.

Skyhawk Therapeutics Partners with Merck KGaA for Innovative Neurological Drug Development #USA #Boston #Skyhawk_Therapeutics #Merck_KGaA #RNA_Modulation